Functional Food Ingredients Patents: Leaders & White Space 2026
- Medicinal-preparation claims dominate. 40 of 43 families sit in A61K, versus 12 in the core food/beverage class A23L — most activity is filed as a drug-adjacent formulation, not as a food product claim.
- Filing is still accelerating, not maturing. Volume dropped to zero at the 2022 midpoint before picking back up, and the most recent full year sits well above the 2017 starting point — this is an active filing curve, not a settled one.
- India leads the receiving offices. 10 filings route through India, ahead of China, the EPO, Israel, the US and WIPO's PCT channel at 4 apiece — a spread that points to a technology still being staked out jurisdiction by jurisdiction.
What this landscape covers
This dataset tracks patent families that combine functional food ingredient, nutraceutical ingredient or food fortification language in the title or abstract with claims touching bioavailability, encapsulation, processing stability, sensory masking or regulatory status, filtered to IPC classes A23L33, A23P10 and A61K9. It spans filings from 2015 through the July 2026 data cut-off, with 43 published families forming the ranking base.
The IPC split is the first signal worth reading closely: this is a delivery-technology dataset as much as a food dataset. A61K's medicinal-preparation coding covers more than three times the record count of A23L's food and beverage coding, which means most applicants are protecting how an active ingredient survives digestion or processing, not the food matrix it sits in.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 43-family dataset: the year-by-year filing count, and the IPC subclasses those families are coded against.
Filing trend, 2017-2026
Filings opened at 1 in 2017, peaked so far at 4 in 2019, fell to 0 at the 2022 midpoint, and reached 2 in the most recent (partial) year — read the last one or two years as undercounted, since publication typically lags filing by around 18 months.
IPC subclass composition
A61K (medicinal preparations) accounts for 40 of the coded records, well ahead of A23L (foods and beverages) at 12; smaller counts in C12N, C05F, C08H, A61P, A61Q and A23G mark adjacent branches — microbial production routes, waste-derived inputs, macromolecule derivatives and cosmetic use — that intersect the core claim space without dominating it.
Shares are the percentage of the 43 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Functional Food Ingredients with Eureka
This page is one run against one query. Ask Eureka your own question about functional food ingredients and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this dataset
Pharmaceutical or neutraceutical formulation (US20120315334A1, Evonik Operations)
The filing claims a formulation with a core containing an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability-promoting agent, wrapped in a polymeric coating for gastrointestinal-targeted release. The bioavailability promoter is specified as a pharmaceutically acceptable protease inhibitor that lifts oral bioavailability of the active ingredient by at least a factor of five compared with a formulation lacking it.Filed 2012-12-13 by Evonik Operations GmbH.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20190000905A1 | Gynostemma pentaphyllum fermented extracts comprising Saponins as an active functional food ingredient and pr… | 9 |
| 2 | CN102524760A | 一种功能性食品配料菊芋粉及其加工方法 | 7 |
| 3 | WO2011103920A2 | Pharmaceutical or neutraceutical formulation | 7 |
| 4 | US8765152B2 | Pharmaceutical or neutraceutical formulation | 7 |
| 5 | WO2020102673A1 | Purification of algal extracts and their applications | 6 |
| 6 | CN119306798A | 一种新型鳕鱼骨促钙吸收肽及其制备方法和应用 | 1 |
| 7 | US20120315334A1 | Pharmaceutical or neutraceutical formulation | 1 |
Citation counts reflect influence within this searched corpus and skew toward older filings; treat them as a marker of what other applicants built on, not of what matters today.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Publication numbers are shown where the record carries one (7 of 7 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three readings of the dataset that matter more than the raw counts on their own.
This is a delivery-vehicle field wearing a food label
The bulk of protected subject matter is bioavailability and release-mechanism engineering coded as a pharmaceutical preparation, not a food composition. A new entrant filing purely on the food-matrix side (A23L) faces a thinner, more open prior-art field than one filing on encapsulation or release chemistry.
The curve dipped and is climbing again
A flat spot at the midpoint followed by renewed filing in the most recent years suggests either a wave of new applicants or a returning cohort refreshing earlier formulation work. Either way, the field has not settled into a mature, low-filing steady state.
No single office dominates the way volume might suggest
India's 10 filings lead a field where China, the EPO, Israel, the US and the PCT route each sit at 4. That even spread across five offices below the leader points to applicants still choosing where to protect rather than defaulting to one home jurisdiction.
A small, recurring collaboration cluster
The strongest pairings repeat across the same handful of organisations rather than spreading widely, which points to a few established partnerships doing most of the joint filing rather than a broad collaborative ecosystem.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to functional food ingredients, with the prior art for and against each one.
Who is active, and where the gate sits
Recent-year momentum across the named assignees is flat: every organisation tracked here shows zero filings in the latest year, consistent with the publication lag rather than a genuine pullback. That makes the co-filing pattern, not year-over-year counts, the more useful signal of who is actually working together.
A recurring industrial partnership anchors the dataset
The pairing that recurs most often in this dataset links two organisations across multiple joint families, alongside separate pairings with individual named inventors, suggesting a stable working relationship on formulation and coating technology rather than one-off collaboration.
Some protection is still inventor-held, not corporate-only
Several of the strongest co-assignee links pair a corporate entity with an individually named inventor-assignee, a structure more common in earlier-stage or spin-out formulation work than in large-portfolio corporate filing.
A small dataset with no runaway leader
At 43 families across the full search window, this is a field of modest total volume rather than one with a dominant portfolio holder. That favours a targeted freedom-to-operate check over a broad landscape clearance.
| Assignee | Recent year | YoY |
|---|---|---|
| Röhm GmbH | 0 | — |
| Evonik Operations GmbH | 0 | — |
| BACK OF THE YARDS ALGAE SCIENCES LLC | 0 | — |
| WINDHAB NORBERT | 0 | — |
| SCHMITT GUNTER | 0 | — |
| ROTH ERNA | 0 | — |
| LIZIO ROSARIO | 0 | — |
| LIEFKE MELANIE | 0 | — |
Where to take this analysis
The trend and IPC data point to specific next steps depending on whether the goal is clearance, sourcing or monitoring.
Run a freedom-to-operate check on encapsulation claims
Given how concentrated the dataset is in A61K bioavailability and release-mechanism claims, a targeted clearance search on coating and penetration-promoter language is more useful here than a broad landscape sweep.
Explore in Patsnap EurekaTrack the co-filing cluster for licensing or partnership signals
The repeated pairing across a small set of organisations suggests an active industrial-academic or industrial-inventor relationship worth watching for licensing moves or new joint filings.
Explore in Patsnap EurekaWatch the under-claimed branches for first-mover filings
Microbial production routes and waste-derived inputs carry only a handful of records each; a well-drafted first claim in either branch would face comparatively light prior art today.
Explore in Patsnap EurekaCommon questions on functional food ingredient patents
In this dataset, a functional food ingredient patent is a filing whose title or abstract uses language like functional food ingredient, nutraceutical ingredient or food fortification, combined with a technical claim touching bioavailability, encapsulation, processing stability, sensory masking or regulatory status. It is further filtered to IPC classes A23L33 (foods for special dietary purposes), A23P10 (food-shaping and treatment processes) and A61K9 (pharmaceutical preparation forms). That last class is why so many records read like drug formulation patents rather than food-product patents.
Because the core technical problem in this field, protecting or delivering an active ingredient through digestion, is coded the same way whether the active ends up in a food, a supplement or a drug. In this dataset 40 of 43 families carry the A61K medicinal-preparation code against only 12 in A23L, the dedicated food and beverage class. Applicants working on the food-matrix side of the problem, rather than the delivery-mechanism side, face a comparatively thinner prior-art field.
The filing trend in this dataset opened at 1 family in 2017, rose to a peak of 4 in 2019, dropped to 0 at the 2022 midpoint, and has since climbed back to 2 in the most recent partial year. That pattern reads as accelerating rather than settling into decline, though the most recent one to two years will look higher once publication catches up, since patent publication typically lags filing by around 18 months.
India leads the receiving offices in this dataset with 10 filings, ahead of China, the European Patent Office, Israel, the United States and the WIPO PCT route, which each carry 4. That relatively even spread below the leader suggests applicants are choosing jurisdictions deliberately rather than defaulting to a single home market, which matters when planning where to seek protection or watch for competitor filings.
The clearest gaps sit in the IPC branches that appear in the dataset but carry only a handful of records each: microbial and genetic-engineering routes to nutraceutical actives (C12N), waste-derived fortification inputs (C05F), natural macromolecule carrier derivatives (C08H), and sensory-masking work aimed specifically at fortified beverages. None of these carries anywhere near the volume seen in the core A61K bioavailability claims, so a well-drafted first claim in any of them would face lighter prior art than the crowded delivery-mechanism space.
Research Functional Food Ingredients in depth with Eureka
Go past this page: query the whole functional food ingredients corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.